Aly-Khan A. Lalani, Department of Medical Oncology, Cross Cancer Institute, University of Alberta presents Proton Pump Inhibitors and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma (mRCC) at the 2016 annual International Kidney Cancer Symposium.
Author: Editor
Chung-Han Lee, MD, PhD, Medical Oncologist, Memorial Sloan Kettering presents Medullary Renal Cell Carcinoma (RCC): Genomics and Treatment Outcomes at the 2016 annual International Kidney Cancer Symposium.
Maria Becerra, Research Fellow at Memorial Sloan Kettering Cancer Center presents Characterization of genomic alterations associated with metastatic tropism in a cohort of patients with renal cell carcinoma at the 2016 annual International Kidney Cancer Symposium.
Thomas Hutson, Memorial Sloan Kettering Cancer Center, New York, NY presents A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mRCC) vs standard of care at the 2016 annual International Kidney Cancer Symposium.
Rana McKay, MD, Assistant Professor of Medicine, HMS/DFCI/BWH presents PD-1/PD-L1 Blockage in Non-Clear Cell RCC at the 2016 annual International Kidney Cancer Symposium.
Toni K. Choueiri Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute presents Savolitinib (volitinib, AZD6094, HMPL-504): Future Directions at the 2016 annual International Kidney Cancer Symposium.
Primo N. Lara, Jr., MD, Professor of Medicine, University of California Davis School of Medicine, Acting Director, UC Davis Comprehensive Cancer Center presents PAPMET trial (SWOG 1500) in Papillary Renal Cell Cancer: Rationale and Current Status at the 2016 annual International Kidney Cancer Symposium.
Laurence Albiges, MD, Gustave Roussy presents Crizotinib In Papillary RCC at the 2016 annual International Kidney Cancer Symposium.
Brian Shuch, MD, Assistant Professor of Urology/Radiology, Yale School of Medicine presents Developments in Biology of Non-Clear Cell RCC at the 2016 annual International Kidney Cancer Symposium.
Debate: Kidney Cancer: Should we explore drug combination strategies in an adjuvant setting?
Priti S. Hegde, PhD, Director, CI Franchise Lead, Biomarkers Genentech Roche presents Blocking VEGF in addition to checkpoint inhibition in RCC at the 2016 annual International Kidney Cancer Symposium.
Paula Ragan, CEO, X4 Pharmaceuticals presents Addressing Unmet Need in ccRCC Through Targeted CXCR4 Blockade at the 2016 annual International Kidney Cancer Symposium.
Christopher Turner, MD, Vice President, Clinical Science presents Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates at the 2016 annual International Kidney Cancer Symposium.
Ian M. Waxman, MD, Bristol-Myers Squibb presents New opportunities for immuno-oncology in renal cell carcinoma at the 2016 annual International Kidney Cancer Symposium.
Moderator Michael B. Atkins , Georgetown-Lombardi Comprehensive Cancer Center participates in a debate: In 2020 Which Approach do you predict will lead to Optimal Outcomes and Why in Kidney Cancer?
Neeraj Agarwal, MD, Associate Professor of Medicine Director, GU Medical Oncology, Huntsman Cancer Institute presents Toxicities with PD-1 Inhibitors: The Price of the Cure at the 2016 annual International Kidney Cancer Symposium.
Tian Zhang, MD, Duke Cancer Institute, Duke University Medical Center presents “Vaccines in Renal Cell Carcinoma: A Lost Cause or the Way Forward?” at the 2016 annual International Kidney Cancer Symposium.
Guru Sonpavde, MD, Associate Professor of Medicine Director, Urologic Oncology, UAB Comprehensive Cancer Center presents Sequencing VEGF and PD-1 Inhibition for RCC at the 2016 annual International Kidney Cancer Symposium.
Hans Hammers MD, PhD, Kidney Cancer Program, UT Southwestern presents PD1 and CTLA4 Inhibition in RCC at the 2016 annual International Kidney Cancer Symposium.
David McDermott, MD, Leader, Kidney Cancer Program Dana-Farber/Harvard Cancer Center presents To Combine: VEGF + PD-1 at the 2016 annual International Kidney Cancer Symposium.
Charles G. Drake MD / PhD, Director GU Medical Oncology, Co-Director Immunotherapy Program, Associate Director for Clinical Research, Herbert Irving Cancer Center at Columbia University presents To Combine or Sequence: Biological Rationale at the 2016 annual International Kidney Cancer Symposium.
Robert G. Uzzo, M.D.Willing G. Pepper Chairman of Surgery Fox Chase Cancer Center, Temple University School of Medicine Chair, Department of Urology, Urological Institute at Einstein Healthcare Network presents Atezolizumab Adjuvant RCC Trial: A Surgical Perspective at the 2016 annual International Kidney Cancer Symposium.
Mohamad E. Allaf, MD, Associate Professor of Urology, Oncology, & BME MEA Endowed Director, Minimally Invasive Surgery Johns Hopkins Medicine presents Phase 3 Perioperative Nivolumab in M0 RCC (PROSPER RCC, ECOG ACRIN 8143) A UROLOGISTS PERSPECTIVE at the 2016 annual International Kidney Cancer Symposium.
Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center presents Atezolizumab Adjuvant Study: Medical Oncologist Perspective at the 2016 annual International Kidney Cancer Symposium.
Lauren C. Harshman MD, Assistant Professor of Medicine, Harvard Medical School, Dana-Farber, presents a strong case for a neoadjuvant/adjvuant approach to priming the immune system before surgery at the 2016 annual International Kidney Cancer Symposium.
Naomi B. Haas, MD, Director, Prostate and Kidney Cancer Program, Associate Professor of Medicine at the Hospital of the University of Pennsylvania presents “Have we learned any lessons from adjuvant VEGF-directed therapy?” at the 2016 annual International Kidney Cancer Symposium.
Bradley C. Leibovich, MD, FACS, Chair, Department of Urology, David C. Utz Professor of Urology, Mayo Clinic, Rochester, MN presents Preoperative 3-D Modeling & Intraoperative Imaging for Renal Surgery at the 2016 annual International Kidney Cancer Symposium.
Jose A. Karam, MD, FACS, Assistant Professor, Department of Urology, MD Anderson asks “Cytoreductive Nephrectomy: Yes, No, Clinical Trial?” at the 2016 annual International Kidney Cancer Symposium.
R. Houston Thompson, MD, Professor of Urology, Mayo Clinic presents Cytoreductive Nephrectomy: Optimizing Surgical Outcomes and Minimizing Complications at the 2016 annual International Kidney Cancer Symposium.
E. Jason Abel, MD, FACS, Associate Professor, Department of Urology, University of Wisconsin presents Cytoreductive nephrectomy in locally advanced renal tumors at the 2016 annual International Kidney Cancer Symposium.
Viraj Master MD PhD FACS, Professor Associate Chair for Clinical Affairs and Quality, Director of Clinical Research Unit Department of Urology, Emory University asks the question “Lymphadenectomy in RCC: Yes, No, Clinical Trial?” at the 2016 annual International Kidney Cancer Symposium.
Ithaar H. Derweesh, M.D., University of California, San Diego asks the question “Neoadjuvant Therapy: Where are we in 2016?” at the 2016 annual International Kidney Cancer Symposium.
Kamran Ahrar, MD, MBA, Professor, Interventional Radiology presents Renal Tumor Ablation: Current Technologies and Outcomes at the 2016 annual International Kidney Cancer Symposium.
Phillip M. Pierorazio, MD, Assistant Professor of Urology and Oncology, Brady Urological Institute, Sidney Kimmel Cancer Center, Johns Hopkins Hospital, Baltimore, Maryland asks the question Active Surveillance For Renal Masses: Where Are We In 2016? at the 2016 annual International Kidney Cancer Symposium.
Alexander Kutikov, MD, FACS, Associate Professor of Urologic Oncology Fox Chase Cancer Center, Philadelphia, PA presents “Renal Biopsy: Always, Sometimes or Never?” at the 2016 annual International Kidney Cancer Symposium.
Brandon Manley presents Characterizing Recurrent And Lethal Small Renal Masses In Clear Cell Renal Cell Carcinoma Using Recurrent Somatic Mutations at the 2016 annual International Kidney Cancer Symposium.
Dr. Nicholas G. Cost, M.D. Assistant Professor, Department of Surgery, Division of Urology University of Colorado Cancer Center presents RCC in Adolescents and Young Adults (AYAs): Diagnosis and Management at the 2016 annual International Kidney Cancer Symposium.
Dr. Karim Touijer, MD, MPH. Memorial Sloan-Kettering Cancer Center presents Surgery for cT1b RCC: Partial Nephrectomy, Radical nephrectomy, Clinical Trial? at the 2016 annual International Kidney Cancer Symposium.
Dr. Daniel Heng MD MPH FRCPC of Tom Baker Cancer Center, University of Calgary @DrDanielHeng presents Renal cell carcinoma prognostication in 2016 at the 2016 annual International Kidney Cancer Symposium.
Dr. Sima Porten, MD MPH, Assistant Professor, Department of Urology UCSF presents Partial Nephrectomy 2016, Techniques, Outcomes, and Selection at the 2016 annual International Kidney Cancer Symposium
Dr. Jamil Syed BS Research Fellow of Yale Department of Urology presents The Incidence and Predictive Factors of Metachronous Bilateral Renal Cell Carcinoma: A SEER Analysis at the2016 annual Kidney Cancer Association meeting
Is stem cell transplant (SCT) a viable option for MPN patients? Noted MPN specialist and researcher, Dr. David Snyder from City of Hope, discusses new refinements to SCT, including the matching process as well as protocols for preparing for transplant. Dr. Snyder stresses that the conversation about SCT should happen early in treatment and should be an ongoing dialogue between patient and specialist. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Stephan Stilgenbauer, MD, PhD of Ulm University, Ulm, Germany, talks about individualized treatment and delivering the right treatment for the right patient in chronic lymphocytic leukemia (CLL). Prof. Stilgenbauer explains that we are now on the road towards individualized treatment. There is data available from genome wide sequencing (GWS) studies that really help identify the landscape of CLL cancer driver mutations. Prof. Stilgenbauer mentions bringing this into clinical trials in the light of the novel agents, to identify the particular subgroups that benefit best from a particular given treatment. Prof. Stilgenbauer is optimistic that the coming months will bring new,…
Barbara Eichhorst, MD of the University of Cologne, Cologne, Germany, discusses how sharing data between groups on cancer can help a progression in the treatment of chronic lymphocytic leukemia (CLL). Dr Eichhorst mentions focusing on the molecular basis of cancer and treating it more according to genetic lesions. There are many things that can be learnt from other diseases, for example, with checkpoint inhibitors in solid tumors. Further, we can learn from chronic myeloid leukemia (CML) where kinase inhibitors have been available for nearly 20 years now; experts have learnt that it is important to get fast and deep remissions.…
Arnon Kater, MD, PhD of the Academic Medical Center, Amsterdam, Netherlands talks about how to overcome mental health issues that may be seen within chronic lymphocytic leukemia (CLL) patients at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany. Prof. Kater explains that when you deal with CLL, who you are never going to cure, considering their quality of life becomes very important. Although it is very challenging, clinicians must help patients understand that they shouldnt be the disease but instead have the disease. In this way it is easier for the patient to live…
Jennifer Woyach, MD of The Ohio State University Comprehensive Cancer Center, Columbus, OH talks developments in chronic lymphocytic leukaemia (CLL) at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany. Dr Woyach explains that this an exciting time for CLL as we are moving away from chemotherapy towards targeted therapies alone or in combination with expectation of good efficacy, good tolerability and hopefully long durations of remission.
Jasmin Bahlo, PhD of University of Cologne, Cologne, Germany talks about the analysis of the projects that are underway at the German CLL Study Group (GCLLSG) at the 2016 International Workshop of the GCLLSG in Cologne, Germany. Dr Bahlo explains that there is a lot of analysis to do; for example there are Phase III trials that are being analysed, there is the data for the CLLM1 trial (NCT01556776), which is being prepared for publication and further, they have a publication on minimal residual disease (MRD) in combination with response to treatment.
Barbara Eichhorst, MD of the University of Cologne, Cologne, Germany, discusses how best to deal with Richters transformation. Dr Eichhorst begins by stating that the best treatment for Richters transformation is to control the chronic lymphocytic leukemia (CLL), so that the transformation will not have a chance to develop. Dr. Eichhorst mentions a presentation given at this years GCLLSG congress, showing the different mutations observed in Richters transformation in comparison to de novo diffuse large B-cell lymphoma (DLBCL). It is already established that Richters is a completely different disease to DLBCL and CLL. As there are so many genetic aberrations…
Federico Caligris-Cappio, MD of Università Vita-Salute San Raffaele, Milan, Italy, talks about new treatment and traditional treatment options for chronic lymphocytic leukemia (CLL) at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany. Prof. Caligris-Cappio explains that whenever there are new drugs, there is a huge temptation to jump to these drugs and forget about the rest. He believes that doctors must think about the particular patient in these situations. All the aspects of the patient, their fears and expectations, must be taken into consideration and weighed up to decide which treatment is best for…
Arnon Kater, MD, PhD of the Academic Medical Center, Amsterdam, Netherlands talks about how he thinks clinicians should talk to chronic lymphocytic leukemia (CLL) patients about their hopes and expectations at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany. He explains that clinicians should not talk about cures to patients. Furthermore, patients should know that CLL is becoming more and more a chronic disease. Further, it is extremely important for quality of life assessments to be done for all the new clinical studies; even though the side effects are often small, having these side…